BioSpace News Archive

Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation therapies for back of the eye disease

AAFA Applauds Walgreens and Kaléo Partnership, Increasing Patient Access to Life-Saving Epinephrine

Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.

Although the dominant story in biopharma patent litigation was the federal appeals court backing the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University over the University of California (UC) on CRISPR patents, there have been other patent decisions of note today as well. Let’s take a look.

Shares of Indiana-based Endocyte have slipped more than 3 percent this morning after the company announced the U.S. Food and Drug Administration accepted radiographic progression-free survival as an alternative primary endpoint in its Phase III VISION trial.

Late-stage trial results show that a combination of Bavencio (avelumab) and Inlyta (axitinib) significantly improved progression-free survival in previously untreated patients with advanced renal cell carcinoma.

Lunaphore Technologies SA and A. Menarini Diagnostics S.r.l. today jointly announce the start of a strategic partnership bringing to the market a new and innovative system, using Lunaphore’s technology.

RSP Systems A/S, the non-invasive diagnostics company, announces that it has completed second closing of its Series B round.

The Onyx ONE Clear Study Builds Upon Body of Clinical Evidence to Inform Individualized DAPT Duration Following Stent Procedures

The University of Maryland School of Pharmacy (UMSOP), in partnership with the U.S. Food and Drug Administration (FDA), is hosting a medical devices workshop: Patient Engagement in Real World Evidence: Lessons Learned and Best Practices.